Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, placebo-controlled, cross-over, phase II, single center
efficacy study of AD981 in patients with obesity hypoventilation syndrome documented by
polysomnography (PSG) and transcutaneous, overnight measurement of CO2 (PtcCO2).
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Auxologico Italiano
Collaborators:
Apnimed Inc. STM Pharma PRO srl University of Florence VIS Ethic Research Srl